Company intelligence / Profile preview
BioCryst Pharmaceuticals, Inc.
Durham, North Carolina, United Statesbiocryst.com ↗
- Ownership
- Public · BCRX
- Employees
- ~580
- Development stage
- Commercial
01
Overview
BioCryst has approved products including ORLADEYO for hereditary angioedema and RAPIVAB/RAPIACTA/PERAMIFLU for influenza. The company has multiple programs in development, with five expected to be in clinical development within 24 months as of November 2023.
- Therapeutic areas
- NephrologyOphthalmologyImmunologyDermatologyHematologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Oral small-molecule therapeuticsProtein therapeuticsInjectable protein therapeutics
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
Torii Pharmaceutical Co.Shionogi & Co., Ltd.Green Cross CorporationNational Institute of Allergy and Infectious DiseasesBiomedical Advanced Research and Development AuthorityU.S. Department of Health and Human ServicesClearside (for SCS Microinjector technology)
04
Financials
- Market cap
- $2.1B
- Total revenue
- $218.3M
- Enterprise value
- $2.2B
Beyond the preview
Go deeper on BioCryst Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioCryst Pharmaceuticals, Inc..